Gene therapy represents a paradigm shift in modern medicine, offering unprecedented opportunities to combat diseases at their ...

TOKYO -- Japanese researchers from Keio University and elsewhere announced Thursday that they have begun a clinical trial on a gene therapy to restore light sensitivity in patients with retinitis ...

Crispr Therapeutics AG has revenue declines but holds strong financials. Promising Sickle Cell therapy & 2025 data readouts ...

Restore Vision Inc., a clinical-stage biotechnology company advancing gene therapies for retinal disorders, today announced that the first patient in its Phase I/II clinical trial with RV-001 has been ...

Total operating expenses for the fourth quarter of 2024 were $287 million, including non-cash stock-based compensation of $40 ...

Biomedical engineers at Duke University have demonstrated a promising new approach that could be used to treat a rare and ...

We think Biogen's neurology, immunology, and focus on rare diseases support a narrow moat. Biogen's strategy has its roots in the 2003 merger of Biogen (Avonex for treating multiple sclerosis, or MS) ...

Elixirgen Therapeutics, Inc. is a clinical-stage biotechnology company focused on the treatment of rare diseases and aging-associated diseases using its ZSCAN4 technology and mRNA platform ...

We recently published a list of 12 Best Italian Stocks to Buy in 2025. In this article, we are going to take a look at where ...

Ugandans with chronic diseases who had taken long without being treated or had lost hope of getting the next lease of life can afford a smile following the launch of stem cell therapy.The Joint ...

REGENXBIO (NASDAQ:RGNX – Get Free Report) was downgraded by analysts at The Goldman Sachs Group from a “buy” rating to a “neutral” rating in a report issued on Tuesday, MarketBeat reports. They ...

Cell-engineering company, MaxCyte, Inc., announced it will acquire SeQure Dx, which focuses on editing assessment services for cell and gene therapies, for $4.5 million. The all-cash deal includes ...